{
     "PMID": "26721370",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20160929",
     "LR": "20160101",
     "IS": "1734-1140 (Print) 1734-1140 (Linking)",
     "VI": "68",
     "IP": "1",
     "DP": "2016 Feb",
     "TI": "Effects of ketamine administration on the phosphorylation levels of CREB and TrKB and on oxidative damage after infusion of MEK inhibitor.",
     "PG": "177-84",
     "LID": "10.1016/j.pharep.2015.08.010 [doi] S1734-1140(15)00297-2 [pii]",
     "AB": "BACKGROUND: Ketamine, an antagonist of N-methyl-d-aspartate (NMDA) receptors, has presented antidepressant effects in basic and clinical studies. The MAPK kinase (MEK) signaling pathway could be a target for novel antidepressant drugs and an important pathway involved in neuronal plasticity. Thus, this study evaluated the effects of the administration of ketamine on the phosphorylation of TrKB and CREB, and oxidative stress parameters in the prefrontal cortex (PFC), hippocampus, amygdala, and nucleus accumbens (NAc) rats, after the inhibition of MAPK pathway (PD184161). METHODS: Male adult Wistar rats were submitted to a surgical procedure to receive a single dose of a pharmacological inhibitor of MAPK (PD184161) at a dose of (0.1mug/mul) or vehicle. Then, they were divided: 1) vehicle+saline; 2) inhibitor PD184161+saline; 3) vehicle+ketamine 15mg/kg; and 4) inhibitor PD184161+ketamine 15mg/kg. RESULTS: MEK inhibitor and ketamine increased the phosphorylation of the transcription factor cAMP response element-binding protein (pCREB) and neurotrophic factor/tropomyosin related kinase B receptor (pTrKB) in the PFC, and decreased pCREB in the hippocampus. The MEK inhibitor abolished ketamine's effects in the hippocampus. In the amygdala, pCREB was decreased, and pTrKB was increased after MEK inhibitor plus ketamine. Ketamine increased the thiobarbituric acid reactive species (TBARS) in the PFC, hippocampus, amygdala, and NAc; MEK inhibitor antagonized these effects. The carbonyl was increased in the PFC by both ketamine and MEK inhibitor, but inhibitor infusion plus ketamine administration reduced this effect. In the amygdala, MEK inhibitor increased carbonyl. CONCLUSION: Ketamine's effects on pCREB, pTrKB, and oxidative stress are mediated, at least in part, by a mechanism dependent of MAPK signaling inhibition.",
     "CI": [
          "Copyright (c) 2015 Institute of Pharmacology, Polish Academy of Sciences.",
          "Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved."
     ],
     "FAU": [
          "Reus, Gislaine Z",
          "Abaleira, Helena M",
          "Titus, Stephanie E",
          "Arent, Camila O",
          "Michels, Monique",
          "da Luz, Jaine R",
          "dos Santos, Maria Augusta B",
          "Carlessi, Anelise S",
          "Matias, Beatriz I",
          "Bruchchen, Livia",
          "Steckert, Amanda V",
          "Ceretta, Luciane B",
          "Dal-Pizzol, Felipe",
          "Quevedo, Joao"
     ],
     "AU": [
          "Reus GZ",
          "Abaleira HM",
          "Titus SE",
          "Arent CO",
          "Michels M",
          "da Luz JR",
          "dos Santos MA",
          "Carlessi AS",
          "Matias BI",
          "Bruchchen L",
          "Steckert AV",
          "Ceretta LB",
          "Dal-Pizzol F",
          "Quevedo J"
     ],
     "AD": "Laboratorio de Neurociencias, Programa de Pos-Graduacao em Ciencias da Saude, Unidade Academica de Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, Brazil; Center for Translational Psychiatry, Department of Psychiatry and Behavioral Sciences, The University of Texas Medical School at Houston, Houston, USA. Electronic address: gislainezilli@hotmail.com. Center for Translational Psychiatry, Department of Psychiatry and Behavioral Sciences, The University of Texas Medical School at Houston, Houston, USA. Center for Translational Psychiatry, Department of Psychiatry and Behavioral Sciences, The University of Texas Medical School at Houston, Houston, USA. Laboratorio de Neurociencias, Programa de Pos-Graduacao em Ciencias da Saude, Unidade Academica de Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, Brazil. Laboratorio de Fisiopatologia Experimental, Programa de Pos-Graduacao em Ciencias da Saude, Unidade Academica de Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, Brazil. Laboratorio de Neurociencias, Programa de Pos-Graduacao em Ciencias da Saude, Unidade Academica de Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, Brazil. Laboratorio de Neurociencias, Programa de Pos-Graduacao em Ciencias da Saude, Unidade Academica de Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, Brazil. Laboratorio de Neurociencias, Programa de Pos-Graduacao em Ciencias da Saude, Unidade Academica de Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, Brazil. Laboratorio de Neurociencias, Programa de Pos-Graduacao em Ciencias da Saude, Unidade Academica de Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, Brazil. Laboratorio de Neurociencias, Programa de Pos-Graduacao em Ciencias da Saude, Unidade Academica de Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, Brazil. Laboratorio de Neurociencias, Programa de Pos-Graduacao em Ciencias da Saude, Unidade Academica de Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, Brazil. Laboratorio de Saude Coletiva, Programa de Pos Graduacao em Saude Coletiva, Unidade Academica de Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, Brazil. Laboratorio de Fisiopatologia Experimental, Programa de Pos-Graduacao em Ciencias da Saude, Unidade Academica de Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, Brazil. Laboratorio de Neurociencias, Programa de Pos-Graduacao em Ciencias da Saude, Unidade Academica de Ciencias da Saude, Universidade do Extremo Sul Catarinense, Criciuma, Brazil; Center for Translational Psychiatry, Department of Psychiatry and Behavioral Sciences, The University of Texas Medical School at Houston, Houston, USA.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20150828",
     "PL": "Poland",
     "TA": "Pharmacol Rep",
     "JT": "Pharmacological reports : PR",
     "JID": "101234999",
     "RN": [
          "0",
          "(2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamid",
          "e)",
          "0 (Aniline Compounds)",
          "0 (Benzamides)",
          "0 (Cyclic AMP Response Element-Binding Protein)",
          "690G0D6V8H (Ketamine)",
          "EC 2.7.10.1 (Receptor, trkB)",
          "EC 2.7.12.2 (Mitogen-Activated Protein Kinase Kinases)"
     ],
     "SB": "IM",
     "MH": [
          "Aniline Compounds/*administration & dosage",
          "Animals",
          "Benzamides/*administration & dosage",
          "Brain/drug effects/metabolism",
          "Cyclic AMP Response Element-Binding Protein/*metabolism",
          "Infusions, Intravenous",
          "Ketamine/*pharmacology",
          "Male",
          "Mitogen-Activated Protein Kinase Kinases/*antagonists & inhibitors",
          "Oxidative Stress/drug effects/*physiology",
          "Phosphorylation/drug effects/physiology",
          "Rats",
          "Rats, Wistar",
          "Receptor, trkB/*metabolism"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "CREB",
          "Depression",
          "Ketamine",
          "MEK",
          "Oxidative stress"
     ],
     "EDAT": "2016/01/02 06:00",
     "MHDA": "2016/09/30 06:00",
     "CRDT": [
          "2016/01/02 06:00"
     ],
     "PHST": [
          "2015/02/19 00:00 [received]",
          "2015/07/31 00:00 [revised]",
          "2015/08/13 00:00 [accepted]",
          "2016/01/02 06:00 [entrez]",
          "2016/01/02 06:00 [pubmed]",
          "2016/09/30 06:00 [medline]"
     ],
     "AID": [
          "S1734-1140(15)00297-2 [pii]",
          "10.1016/j.pharep.2015.08.010 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Pharmacol Rep. 2016 Feb;68(1):177-84. doi: 10.1016/j.pharep.2015.08.010. Epub 2015 Aug 28.",
     "term": "hippocampus"
}